Isonid 300 mg Tablet

    Isonid 300 mg

    Isoniazid

    Category: Tablet

    Manufacturer: G. A. Company Ltd.

    Uses of Isonid: - Tuberculosis (TB) Tuberculosis Acute liver disease or history of hepatic damage during INH therapy; hypersensitivity.
    How to use Isoniazid: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Isoniazid is to be taken empty stomach. Avoid Isoniazid with tyramine-rich food such as cheese, smoked fish, meats and some types of beer. Administration: Should be taken on an empty stomach. Best taken on an empty stomach 1 hr before or 2 hr after meals. May be taken w/ meals to reduce GI discomfort. Adult Dose: Oral Active Tuberculosis Disease 5 mg/kg PO qDay, not to exceed 300 mg qDay 15 mg/kg PO up; not to exceed 900 mg 1-3 times/week Used in multi-drug regimen containing rifampin (or ribabutin or rifapentin), pyrazinamide, and ethambutol Latent Tuberculosis Infection Treatment of latent TB infection greatly reduces the risk that TB infection will progress to acitve disease >30 kg: 300 mg PO qDay x9 months Child Dose: Active Tuberculosis Disease 10-15 mg/kg PO qDay; not to exceed 300 mg/day OR 20-30 mg/kg (up to 900 mg) 2 times/week Used in multi-drug regimen Latent Tuberculosis Infection Treatment of latent TB infection greatly reduces the risk that TB infection will progress to acitve disease 10-15 mg/kg PO qDay; not to exceed 300 mg/day Renal Dose: Renal impairment: Severe: Dose reduction may be needed.
    Inhibit the hepatic metabolism of antiepileptics (e.g. carbamazepine, ethosuximide, primidone, phenytoin), benzodiazepines (e.g. diazepam, triazolam), chlorzoxazone, theophylline, disulfiram, sometimes leading to increased toxicity. Increased metabolism of enflurane, resulting in potentially nephrotoxic levels of fluoride. Increased concentrations and enhanced effects or toxicity of clofazimine, cycloserine and warfarin. Reduced absorption w/ Al-containing antacids. Increased risk of peripheral neuropathy w/ zalcitabine and stavudine.
    Acute liver disease or history of hepatic damage during INH therapy; hypersensitivity.
    Common - Peripheral neuropathy (tingling and numbness of feet and hand) - Increased liver enzymes - Hepatitis (viral infection of liver) - Jaundice >10% Mild incr LFTs (10-20%),Peripheral neuropathy (dose-related incidence, 10-20% incidence with 10 mg/kg/d) Loss of appetite,Nausea,Vomiting,Stomach pain,Weakness 1-10% Dizziness,Slurred speech,Lethargy,Progressive liver damage (increases with age; 2.3% in pts > 50 yo),Hyperreflexia <1% Agranulocytosis,Anemia,Megaloblastic anemia,Thrombocytopenia,Systemic lupus erythematosus,Seizure Potentially Fatal: Hepatotoxicity.
    Precaution: Renal or hepatic impairment; convulsive disorders; history of psychosis; patients at risk of neuropathy or pyridoxine deficiency eg, diabetic, alcoholic, malnourished, uraemic, infected with HIV. Careful monitoring of hepatic function is necessary for black and hispanic women. Check hepatic function before and during treatment. Pregnancy and lactation. Lactation: distributed into milk but safe for nursing infants
    Anti-Tubercular Chemotherapeutics
    Isoniazid inhibits the synthesis of mycoloic acids in susceptible bacteria which results in loss of acid-fastness and disruption of bacterial cell wall. At therapeutic levels, it is bacteriocidal against actively growing intracellular and extracellular Mycobacterium tuberculosis organisms.
    Pregnancy Category C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risksLactation: distributed into milk but safe for nursing infants
    Profile avater

    Samm Care